Nerve Injury – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Nerve Injury – Pipeline Review, H2 2016’, provides an overview of the Nerve Injury pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nerve Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nerve Injury and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Nerve Injury

The report reviews pipeline therapeutics for Nerve Injury by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Nerve Injury therapeutics and enlists all their major and minor projects

The report assesses Nerve Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Nerve Injury

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Nerve Injury

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Nerve Injury pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Biogen, Inc.

BrainStorm Cell Therapeutics Inc.

Calico LLC

F. Hoffmann-La Roche Ltd.

Human Stem Cells Institute

Medtronic plc

Neuralstem, Inc.

Neurotune AG

SanBio, Inc.

TissueGene, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Nerve Injury Overview 7

Therapeutics Development 8

Pipeline Products for Nerve Injury - Overview 8

Pipeline Products for Nerve Injury - Comparative Analysis 9

Nerve Injury - Therapeutics under Development by Companies 10

Nerve Injury - Therapeutics under Investigation by Universities/Institutes 11

Nerve Injury - Pipeline Products Glance 12

Clinical Stage Products 12

Early Stage Products 13

Nerve Injury - Products under Development by Companies 14

Nerve Injury - Products under Investigation by Universities/Institutes 15

Nerve Injury - Companies Involved in Therapeutics Development 16

Biogen, Inc. 16

BrainStorm Cell Therapeutics Inc. 17

Calico LLC 18

F. Hoffmann-La Roche Ltd. 19

Human Stem Cells Institute 20

Medtronic plc 21

Neuralstem, Inc. 22

Neurotune AG 23

SanBio, Inc. 24

TissueGene, Inc. 25

Nerve Injury - Therapeutics Assessment 26

Assessment by Monotherapy Products 26

Assessment by Target 27

Assessment by Mechanism of Action 29

Assessment by Route of Administration 31

Assessment by Molecule Type 33

Drug Profiles 35

3K3A-APC - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

CLP-257 - Drug Profile 37

Product Description 37

Mechanism Of Action 37

R&D Progress 37

MDT-15 - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Neovasculgen - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

NSI-566 - Drug Profile 40

Product Description 40

Mechanism Of Action 40

R&D Progress 40

NT-1654 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

raxatrigine hydrochloride - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

SB-618 - Drug Profile 52

Product Description 52

Mechanism Of Action 52

R&D Progress 52

Small Molecules for Peripheral Nerve Injury - Drug Profile 53

Product Description 53

Mechanism Of Action 53

R&D Progress 53

Small Molecules to Activate NAMPT for Neurological Disorders - Drug Profile 54

Product Description 54

Mechanism Of Action 54

R&D Progress 54

Stem Cell Therapy for Neurodegenerative Disorders - Drug Profile 55

Product Description 55

Mechanism Of Action 55

R&D Progress 55

Synthetic Peptides to Inhibit CaMKII for Stroke and Nerve Injury - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

TG-N - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

U-2902 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

Nerve Injury - Dormant Projects 67

Nerve Injury - Discontinued Products 68

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development for Nerve Injury, H2 2016 8

Number of Products under Development for Nerve Injury – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Number of Products under Investigation by Universities/Institutes, H2 2016 11

Comparative Analysis by Clinical Stage Development, H2 2016 12

Comparative Analysis by Early Stage Development, H2 2016 13

Products under Development by Companies, H2 2016 14

Products under Investigation by Universities/Institutes, H2 2016 15

Nerve Injury – Pipeline by Biogen, Inc., H2 2016 16

Nerve Injury – Pipeline by BrainStorm Cell Therapeutics Inc., H2 2016 17

Nerve Injury – Pipeline by Calico LLC, H2 2016 18

Nerve Injury – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 19

Nerve Injury – Pipeline by Human Stem Cells Institute, H2 2016 20

Nerve Injury – Pipeline by Medtronic plc, H2 2016 21

Nerve Injury – Pipeline by Neuralstem, Inc., H2 2016 22

Nerve Injury – Pipeline by Neurotune AG, H2 2016 23

Nerve Injury – Pipeline by SanBio, Inc., H2 2016 24

Nerve Injury – Pipeline by TissueGene, Inc., H2 2016 25

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Stage and Target, H2 2016 28

Number of Products by Stage and Mechanism of Action, H2 2016 30

Number of Products by Stage and Route of Administration, H2 2016 32

Number of Products by Stage and Molecule Type, H2 2016 34

Nerve Injury – Dormant Projects, H2 2016 67

Nerve Injury – Discontinued Products, H2 2016 68

List of Figures

List of Figures

Number of Products under Development for Nerve Injury, H2 2016 8

Number of Products under Development for Nerve Injury – Comparative Analysis, H2 2016 9

Number of Products under Development by Companies, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 13

Assessment by Monotherapy Products, H2 2016 26

Number of Products by Targets, H2 2016 27

Number of Products by Stage and Targets, H2 2016 27

Number of Products by Mechanism of Actions, H2 2016 29

Number of Products by Stage and Mechanism of Actions, H2 2016 29

Number of Products by Routes of Administration, H2 2016 31

Number of Products by Stage and Routes of Administration, H2 2016 31

Number of Products by Molecule Types, H2 2016 33

Number of Products by Stage and Molecule Types, H2 2016 33

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports